AbbVie Invests $195 Million in US API Production
AbbVie announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the US.
This expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the US to support innovation and expand critical manufacturing capabilities and capacity broadly.
Active pharmaceutical ingredient (API) manufacturing is a complex and multi-step process that involves producing the active components responsible for the therapeutic effects of medications. The new North Chicago API facility will expand AbbVie's chemical synthesis capabilities in the US, supporting domestic production of current and next-generation neuroscience, immunology, and oncology medicines.
"Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the US to support future medical breakthroughs," said Robert A. Michael, Chairman and CEO, AbbVie. "This is an important step to maintain US leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."
Construction of the new North Chicago API facility will begin in fall 2025, with the site projected to be fully operational in 2027. The facility will expand AbbVie's existing US manufacturing footprint, which supports more than 6,000 jobs across 11 US manufacturing sites and thousands of additional jobs at suppliers around the country. This investment furthers AbbVie's long-term commitment to Illinois, where it is headquartered, and includes more than 11,000 employees.
